Brief Reports
Copyright ©The Author(s) 2004.
World J Gastroenterol. Aug 1, 2004; 10(15): 2295-2298
Published online Aug 1, 2004. doi: 10.3748/wjg.v10.i15.2295
Table 1 Level of serum ALT, AST and liver Hyp
GroupnALT (U/L)AST (U/L)Liver Hyp (μg/mgprot)
Control1286.0 ± 17.7329 ± 4010.02 ± 1.05
Model111 954 ± 576d2735 ± 786d26.47 ± 11.24d
High-dose group9989 ± 576ad1 584 ± 988c15.01 ± 7.59b
Medium-dose group10759 ± 380bc1259 ± 829a9.89 ± 3.74b
Low-dose group101 003 ± 530ad1 650 ± 928c10.06 ± 2.58b
Table 2 Serum levels of HA, LN, PIIIP and type IV collagen
GroupnPIIIP (ng/mL)Type IV collagen (ng/mL)LN (ng/mL)HA (ng/mL)
Control120.34 ± 0.6718.47 ± 3.4310.07 ± 1.7417.96 ± 5.86
Model113.26 ± 0.69d77.68 ± 20.23d31.62 ± 5.84d42.74 ± 7.04d
High-dose group92.01 ± 0.40bd39.14 ± 4.97 bd16.32 ± 2.73bd21.71 ± 5.69b
Medium-dose group101.47 ± 0.46bd25.64 ± 4.68b14.87 ± 1.45 bd20.68 ± 5.85b
Low-dose group101.84 ± 0.27bd29.09 ± 2.78b17.02 ± 2.74 bd24.18 ± 7.89b
Table 3 Pathological observation of liver condition
GroupnLiver condition
U
0IIIIIIIV
Model1100038
High-dose group9023312.98a
Medium-dose group10044204.01b
Low-dose group10024313.75b